Paper · 28736636
Biological agents in gastrointestinal cancers: adverse effects and their management.
Arora N and 2 others. J Gastrointest Oncol, 2017. Cited by 25 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Biological agents in gastrointestinal cancers: adverse effects and their management. Papers, record 28736636. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28736636
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References108
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17,010,747 | Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. | J Am Acad Dermatol | 2006 | https://conductscience.org/library/papers/17010747 | PubMed |
| 2 | 23,724,867 | Nivolumab plus ipilimumab in advanced melanoma. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23724867 | PubMed |
| 3 | 20,680,104 | Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. | Curr Oncol | 2010 | https://conductscience.org/library/papers/20680104 | PubMed |
| 4 | 17,239,291 | Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. | Clin Lung Cancer | 2006 | https://conductscience.org/library/papers/17239291 | PubMed |
| 5 | 26,082,660 | Cancer therapy and cardiovascular risk: focus on bevacizumab. | Cancer Manag Res | 2015 | https://conductscience.org/library/papers/26082660 | PubMed |
| 6 | 25,945,023 | Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. | World J Gastroenterol | 2015 | https://conductscience.org/library/papers/25945023 | PubMed |
| 7 | 27,214,209 | Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. | Br J Dermatol | 2016 | https://conductscience.org/library/papers/27214209 | PubMed |
| 8 | 21,422,411 | Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21422411 | PubMed |
| 9 | 24,451,730 | Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. | Am Soc Clin Oncol Educ Book | 2012 | https://conductscience.org/library/papers/24451730 | PubMed |
| 10 | 25,742,420 | Hypertension in patients with cancer. | Arq Bras Cardiol | 2015 | https://conductscience.org/library/papers/25742420 | PubMed |
1 to 10 of 108
See all 108 referencesCited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,649,986 | Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649986 | PubMed |
| 42,358,356 | Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42358356 | PubMed |
| 42,024,175 | Evolving therapeutics in colorectal cancer peritoneal metastases. | Cancer Metastasis Rev | 2026 | https://conductscience.org/library/papers/42024175 | PubMed |
| 40,537,738 | Amniotic membrane promotes doxorubicin potency by suppressing SH-SY5Y neuroblastoma cell angiogenesis. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40537738 | PubMed |
| 39,886,668 | Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer. | Front Oncol | 2024 | https://conductscience.org/library/papers/39886668 | PubMed |
| 38,605,419 | Cancer therapy related cardiac dysfunction as a result of Panitumumab. | Cardiooncology | 2024 | https://conductscience.org/library/papers/38605419 | PubMed |
| 38,254,839 | Exploring the Spectrum of VEGF Inhibitors' Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38254839 | PubMed |
| 35,127,324 | Sudden and severe cardiotoxicity induced with pembrolizumab, its clinical course, therapeutic intervention, and outcome. | Int Cancer Conf J | 2022 | https://conductscience.org/library/papers/35127324 | PubMed |
| 33,811,514 | Chemotherapy-induced bowel ischemia: diagnostic imaging overview. | Abdom Radiol (NY) | 2022 | https://conductscience.org/library/papers/33811514 | PubMed |
| 33,767,971 | Systemic adverse effects and toxicities associated with immunotherapy: A review. | World J Clin Oncol | 2021 | https://conductscience.org/library/papers/33767971 | PubMed |
1 to 10 of 16
See all 16 cited byGenes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGFR | 1,956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2,064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| VEGFA | 7,422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28736636
GET https://conductscience.org/api/papers/v1/28736636/references?page=2